AdAlta Limited (ASX:1AD) is a highly innovative drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, that have the potential to treat some of today’s most challenging medical conditions.
What is an i-body?
An i-body is a unique human protein that combines the advantages of small molecules (for stability) and antibodies (with a high affinity and specificity for treating certain illnesses) in one powerful treatment. The i-body has a unique long loop that can bind to a diverse range of targets meaning that it has wide applicability across many diseases.
The Company’s lead i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. There is a high-unmet medical need for effective treatments.
AdAlta is continuing further discovery and development of the i-body platform, directed towards other disease targets for in-house development or partnering.
Both AdAlta’s i-body technology platform and lead i-body drug candidate, AD-214, are protected by a strong portfolio of worldwide granted patents and pending applications.